Veterans Affairs Salt Lake City Health Care System Salt Lake City UT.
North Florida/South Georgia Veterans Affairs Health Care System Gainesville FL.
J Am Heart Assoc. 2021 Dec 21;10(24):e022758. doi: 10.1161/JAHA.121.022758. Epub 2021 Nov 19.
Over the past decade, direct oral anticoagulants (DOACs) have contributed to a major paradigm shift in thrombosis management, replacing vitamin K antagonists as the most commonly prescribed anticoagulants in many countries. While DOACs provide distinct advantages over warfarin (eg, convenience, simplicity, and safety), they are frequently associated with inappropriate prescribing and adverse events. These events have prompted regulatory agencies to mandate oversight, which individual institutions may find difficult to comply with given limited resources. Veterans Health Administration (VHA) has leveraged technology to develop the DOAC Population Management Tool (PMT) to address these challenges. This tool has empowered VHA to update a 60-year standard of care from one-to-one provider-to-patient anticoagulation monitoring to a population-based management approach. The DOAC PMT allows for the oversight of all patients prescribed DOACs and leads to intervention only when clinically indicated. Using the DOAC PMT, facilities across VHA have maximized DOAC oversight while minimizing resource usage. Herein, we discuss how the DOAC PMT was conceived, developed, and implemented, along with the challenges encountered throughout the process. Additionally, we share the impact of the DOAC PMT across VHA, and the potential of this approach beyond anticoagulation and VHA.
在过去的十年中,直接口服抗凝剂(DOACs)在血栓管理方面带来了重大的观念转变,在许多国家取代了维生素 K 拮抗剂,成为最常开的抗凝剂。虽然 DOACs 相对于华法林(例如方便、简单和安全)具有明显优势,但它们经常与不适当的处方和不良事件有关。这些事件促使监管机构要求进行监管,而鉴于有限的资源,个别机构可能难以遵守。退伍军人健康管理局(VHA)利用技术开发了 DOAC 人群管理工具(PMT)来应对这些挑战。该工具使 VHA 能够将 60 年来的护理标准从一对一的医患抗凝监测更新为基于人群的管理方法。DOAC PMT 允许对所有开 DOAC 的患者进行监督,只有在临床需要时才进行干预。VHA 中的各个机构都使用 DOAC PMT 来最大限度地加强 DOAC 的监督,同时将资源的使用最小化。在此,我们讨论了 DOAC PMT 的构思、开发和实施方式,以及在整个过程中遇到的挑战。此外,我们还分享了 DOAC PMT 在 VHA 中的影响,以及这种方法在抗凝治疗和 VHA 之外的潜在应用。
J Am Heart Assoc. 2021-12-21
J Thromb Thrombolysis. 2021-7
BMC Health Serv Res. 2020-4-3
JAMA Netw Open. 2021-12-1
J Am Heart Assoc. 2019-8-23
Circ Cardiovasc Qual Outcomes. 2021-11
Pharmacotherapy. 2017-9-6
J Thromb Haemost. 2025-3
Fed Pract. 2023-11
J Thromb Thrombolysis. 2023-11
J Thromb Thrombolysis. 2021-7
J Thromb Thrombolysis. 2019-4-10
J Am Coll Cardiol. 2017-6-13